Friedreich ataxia (FRDA) is a devastating neurodegenerative orphan disease that affects children and young adults, and has no approved therapy. The disease progressively brings patients to severe disability and significantly reduc...
Friedreich ataxia (FRDA) is a devastating neurodegenerative orphan disease that affects children and young adults, and has no approved therapy. The disease progressively brings patients to severe disability and significantly reduces life expectancy. The genetic defect underlying the disease causes FRDA patients to produce only low amounts of the mitochondrial protein frataxin, compared to normal subjects. Low frataxin results in the accelerated death of peripheral sensory neurons, causing the disease. Goal of any tentative specific therapy is therefore to increase frataxin levels in FRDA patients. Building on our original discovery that unveiled the mechanism of physiological frataxin degradation, we are developing new chemical entities that manage to increase frataxin in FRDA patients cells by preventing the degradation of frataxin. This effort is currently funded by an ERC Advanced Grant (Friedreich Ataxia Seeks Therapy – FAST, project number 293699).
We now plan to bring some of the most promising compounds emerging from the above mentioned ERC-funded project, to the proof of concept (POC) of efficacy in living sensory neurons derived from FRDA patients. This will be achieved by demonstrating that our compounds are able to increase frataxin in sensory neurons generated from patient-derived induced pluripotent stem cells. A defined path for the further de-risking and development of compounds that have reached the POC stage, has been discussed together with Cydan Development, the leading orphan drug accelerator, and the VC firm Kurma Partners.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.